Company intelligence
Sarah Cannon Research Institute
A leading oncology research organization conducting community-based clinical trials.
About Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients for more than three decades, SCRI is a leader in drug development. We have conducted more than 900 first-in-human clinical trials since our inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. In 2022, SCRI formed a joint venture with former US Oncology Research to expand clinical trial access across the country. SCRI’s research network brings together approximately 1,500 physicians who are enrolling patients to clinical trials at over 200 locations in more than 20 states across the U.S.
Verified activity
Signals from Sarah Cannon Research Institute
4 published signals
Research & Knowledge
Sarah Cannon Research Institute launched the Accelero protocol feedback and site engagement initiative to streamline multi-site trials and reduce administrative bottlenecks.
Reported by Erika Hamilton, MD, FASCO
Legal & Regulatory
Sarah Cannon Research Institute received FDA approval for a new oral SERD called Camizestrant in 1L breast cancer, approved by the FDA.
Reported by Erika Hamilton, MD, FASCO
Research & Knowledge
Sarah Cannon Research Institute published findings from the UPBEAT study showing that depression and psychological stress made the biggest difference in whether survivors experienced fatigue up to two years after chemotherapy started.
Reported by Erika Hamilton, MD, FASCO
Presence & Recognition
Sarah Cannon Research Institute attended the 40th Annual Texas Oncology Shareholders Meeting to share updates on the landscape of cancer clinical trials.
Reported by Noelle Cloven